U.S. to tackle the problem of drug shortages using AI, and legislation, among others

Sources reveal U.S. has been facing drug shortages every quarter since 2014. About 150 to 300 drugs have been in short supply in the country, these include painkillers, anesthetics, cancer drugs, injectable morphine, and medicines for mental illness, among others.

A bipartisan group of 31 U.S. senators and 104 members of the House of Representatives drafted

According to reports of the Food and Drug Administration, the number of ongoing drug shortages escalated, while some even lasting for longer than eight years. An analysis done by the FDA in early 2020 further revealed that there were incremental improvements, however drug shortages continue to remain on the rise.

Drug shortages have an adverse impact on clinical, humanistic and economic requirements. Furthermore, specialty manufacturers which produce lifesaving cancer drugs, or life-creating fertility drugs, along with drugs to combat chronic diseases, the paucity then may also affect the patient’s well-being.

Addressing such urgent issues, the FDA has updated a 2020 report which recommends legislative proposals in President Trump’s 2020 budget. Experts however feel it is difficult to find a single solution to the problem.

The FDA however has suggested significant solutions such as- implementation of education to supply-chain stakeholders and legislation, especially focusing on drug shortages on patients and factors contributing to them.

Secondly, introducing a rating system which evaluates product quality to incentivize drug manufacturers and focus on the quality management for facilities.

Thirdly, creating a sustainable private sector contract to ensure reliable supply of medically imported drugs.

Experts however underline the importance of better supply-and demand forecast among parties for eliminating negative outcomes associates with drug shortages.